97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience

Detalles Bibliográficos
Autores principales: Angelis, V., McFarlane, P., Cunningham, N., Gennatas, S., Johnston, S.R.D., Okines, A., McGrath, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/
http://dx.doi.org/10.1016/j.annonc.2021.03.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106264/
http://dx.doi.org/10.1016/j.annonc.2021.03.111

Ejemplares similares